After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

Cola, Spotify, Starbucks, and more. From missed profits to tariff tensions, here's what investors need to know about the ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.

The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts ...

Pfizer’s PFE $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...